Navigation Links
Biomarker predicts disease recurrence in colorectal cancer
Date:2/17/2009

(PHILADELPHIA) Findings published in the Journal of the American Medical Association by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurrence in patients with colorectal cancer.

Detection of the biomarker, guanylyl cyclase 2C (GUCY2C), indicates the presence of occult metastases in lymph nodes that may not have been identified by current cancer staging methods, according to Scott Waldman, M.D., Ph.D., chairman of the Department of Pharmacology and Experimental Therapeutics at Jefferson Medical College of Thomas Jefferson University.

According to Dr. Waldman, who is also the Samuel M.V. Hamilton Professor of Clinical Pharmacology in the Department of Medicine at Jefferson Medical College, colorectal cancer that has metastasized, or spread, to the regional lymph nodes carries a worse prognosis and a higher risk for recurrence. However, these metastases are often missed, and the cancer is understaged.

"One of the unmet needs in colorectal cancer is an accurate staging method to determine how far the disease has spread," said Dr. Waldman, who is also director of the Gastrointestinal Malignancies Program at the Kimmel Cancer Center at Jefferson. "The current standard method, histopathology, is imperfect since it only involves looking at a very small sample of the regional lymph nodes under a microscope. There is no way to know whether occult metastases are present in the rest of the tissue."

Dr. Waldman and his colleagues conducted a prospective, multicenter study of 257 patients with colorectal cancer that had no metastases identified in the lymph nodes (node-negative) according to current standards. They analyzed the lymph nodes for GUCY2C expression using a technique called reverse transcriptase-polymerase chain reaction (RT-PCR). This technique, according to Dr. Waldman, amplifies the sensitivity to detect cancer cells compared to histopathology.

The majority of patients 87.5 percent had lymph nodes that were positive for GUCY2C. Among those patients, 20.9 percent developed recurrent disease. By comparison, only 6.3 percent of the patients whose lymph nodes were negative for GUCY2C developed recurrent disease.

The patients were followed for a median of 24 months for disease recurrence or death. Indeed, patients who expressed GUCY2C had a shorter time to recurrence and a shorter disease-free survival. The prognostic value of the marker persisted even after a multivariate analysis that took other known prognostic factors into account.

According to Dr. Waldman, 20 to 30 percent of patients diagnosed with node-negative colorectal cancer experience disease recurrence within five years. This is approximately the same rate of recurrence as that for some categories of patients diagnosed with node-positive disease. These observations suggest that there are occult metastases in the lymph nodes of node-negative patients at the time of diagnosis. GUCY2C specifically identifies these occult metastases that indicate risk for recurrent disease.

"Beyond predicting disease recurrence, detecting this biomarker could be useful for identifying patients who might benefit from treatment with adjuvant chemotherapy, which is specifically given to patients with node-positive disease," Dr. Waldman said.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-6300
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Major study on DiagnoCures GCC biomarker published in Jama
2. Researchers ID Biomarker for Fatal Prostate Cancer
3. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
4. MDS Analytical Technologies Laser Capture Microdissection Helps Facilitate Discovery of Potential New Colon-Cancer Biomarker
5. Frost & Sullivan Lauds Toscana Biomarkers Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases
6. Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development
7. Biomarkers improve ischemic stroke prediction
8. Biomarkers: What can they tell us
9. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
10. Common painkillers lower levels of prostate cancer biomarker
11. Biomarkers May Help Spot, Track Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... Ten outstanding teachers in the Greater Houston area will be ... a visit by a Houston Texans player, two tickets to a Texans game, and ... can visit texanschecking.com/stars to nominate their favorite teacher with an essay of no more ...
(Date:8/16/2017)... ATLANTA, Georgia (PRWEB) , ... August 16, 2017 ... ... practice in Atlanta, opened their doors. They celebrate 30 years in business this ... to create an up-to-date, inviting, tranquil space to serve their patients. , ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... ... A global leader in the treatment of clubfoot, CURE International India ... the country one step closer to eliminating clubfoot as a lifelong disability by 2030. ... to enroll 10,000 children in the clubfoot treatment program in this year alone. , ...
(Date:8/16/2017)... Georgia (PRWEB) , ... August 16, 2017 , ... Fusion ... distribute premium original programming over four countries and millions of viewers in a partnership ... to rent or buy On-Demand and fully available on Blu Ray disc in 2018. ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and ... driving up healthcare costs and threatening outcomes, were problems ... supply and IVD industry that support them, met this ... market researcher said that drugs of abuse, procalcitonin and ... sessions at the organization,s 69th meeting in ...
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the ... in the Washington D.C. metropolitan area. ... delivery of medications through the convenience of its patient-friendly mobile ... within one hour to any location in D.C. ... invaluable service to Washington D.C. ," says ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation technologies, announced ... to support its strategic sales plan in Maryland ... 7D Surgical has entered into an exclusive sales representative agreement ... within those markets. ... Spartan Medical Purchases 7D Surgical ...
Breaking Medicine Technology: